- EyePoint Pharmaceuticals has just introduced two new treatments, YUTIQ and DEXYCU, both involve the slow release of steroids to prevent eye infections.
- Most of the elements for successful market penetration are already in place, and these markets are substantial.
- Depending on the speed of growth, the company might need another financing.
- While speculative, it’s a high-risk, high-reward situation.
EyePoint Pharmaceuticals Is Eyeing 2 Big Market Opportunities
August 31st, 2019 · No Comments